Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 171

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial

Open access
Griffiths, James, Jenkins, Paula, Vargova, Monika, Bowler, Ursula, Juszczak, Edmund, King, Andrew, Linsell, Louise, Murray, David, Partlett, Christopher, Patel, Mehali, Berrington, Janet, Dorling, Jon, Embleton, Nicholas D, Heath, Paul T, Oddie, Sam, McGuire, William, Ainsworth, Sean, Boyle, Elaine, Clarke, Paul, Craig, Stanley, Johnson, Kathryn, Mactier, Helen, Scorrer, Tim, Ledwidge, Mary, Story, Imogen, Holder, Gemma, Ohadike, Pamela, Ellis, Sarah, Vaikute, Rima, Gowda, Girish, Yates, Helen, Garg, Shalabh, Pilling, Elizabeth, Roehr, Charles, Batra, Dushyant, Gibson, David, Johnson, Mark, Kumar, Yadlapalli, Bartle, David, Peters, Colin, Quine, David, Gupta, Richa, Matthes, Jean, Kennea, Nigel, Reynolds, Peter, Geethanath, Ruppa, Janakiraman, Sundaram, Vasu, Vimal, Manjunatha, C.M. · 2019 · The Lancet

Abstract

BACKGROUND: Infections acquired in hospital are an important cause of morbidity and mortality in very preterm infants. Several small trials have suggested that supplementing the enteral diet of very preterm infants with lactoferrin, an antimicrobial protein processed from cow's milk, prevents infections and associated complications. The aim of this large randomised controlled trial was to collect data to enhance the validity and applicability of the evidence from previous trials to inform practice. METHODS: In this randomised placebo-controlled trial, we recruited very preterm infants born before 32 weeks' gestation in 37 UK hospitals and younger than 72 h at randomisation. Exclusion criteria were presence of a severe congenital anomaly, anticipated enteral fasting for longer than 14 days, or no realistic prospect of survival. Eligible infants were randomly assigned (1:1) to receive either enteral bovine lactoferrin (150 mg/kg per day; maximum 300 mg/day; lactoferrin group) or sucrose (same dose; control group) once daily until 34 weeks' postmenstrual age. Web-based randomisation minimised for recruitment site, gestation (completed weeks), sex, and single versus multifetal pregnancy. Parents, caregivers, and outcome assessors were unaware of group assignment. The primary outcome was microbiologically confirmed or clinically suspected late-onset infection (occurring >72 h after birth), which was assessed in all participants for whom primary outcome data was available by calculating the relative risk ratio with 95% CI between the two groups. The trial is registered with the International Standard Randomised Controlled Trial Number 88261002. FINDINGS: We recruited 2203 participants between May 7, 2014, and Sept 28, 2017, of whom 1099 were assigned to the lactoferrin group and 1104 to the control group. Four infants had consent withdrawn or unconfirmed, leaving 1098 infants in the lactoferrin group and 1101 in the sucrose group. Primary outcome data for 2182 infants (1093 [99·5%] of 1098 in the lactoferrin group and 1089 [99·0] of 1101 in the control group) were available for inclusion in the modified intention-to-treat analyses. 316 (29%) of 1093 infants in the intervention group acquired a late-onset infection versus 334 (31%) of 1089 in the control group. The risk ratio adjusted for minimisation factors was 0·95 (95% CI 0·86-1·04; p=0·233). During the trial there were 16 serious adverse events for infants in the lactoferrin group and 10 for infants in the control group. Two events in the lactoferrin group (one case of blood in stool and one death after intestinal perforation) were assessed as being possibly related to the trial intervention. INTERPRETATION: Enteral supplementation with bovine lactoferrin does not reduce the risk of late-onset infection in very preterm infants. These data do not support its routine use to prevent late-onset infection and associated morbidity or mortality in very preterm infants. FUNDING: UK National Institute for Health Research Health Technology Assessment programme (10/57/49).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)32221-9

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 171

Metadata

Authors
Griffiths, J., Jenkins, P., Vargova, M., Bowler, U., Juszczak, E., King, A., Linsell, L., Murray, D., Partlett, C., Patel, M., Berrington, J., Dorling, J., Embleton, N. D., Heath, P. T., Oddie, S., McGuire, W., Ainsworth, S., Boyle, E., Clarke, P., Craig, S., Johnson, K., Mactier, H., Scorrer, T., Ledwidge, M., Story, I., Holder, G., Ohadike, P., Ellis, S., Vaikute, R., Gowda, G., Yates, H., Garg, S., Pilling, E., Roehr, C., Batra, D., Gibson, D., Johnson, M., Kumar, Y., Bartle, D., Peters, C., Quine, D., Gupta, R., Matthes, J., Kennea, N., Reynolds, P., Geethanath, R., Janakiraman, S., Vasu, V., & Manjunatha, C. M.
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-02
Volume
393
Issue
10170
Pages
423-433
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2910722263
Cited by
171
References
4
FWCI
17.06
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)32221-9
The paper
Griffiths, J., Jenkins, P., Vargova, M., Bowler, U., Juszczak, E., King, A., Linsell, L., Murray, D., Partlett, C., Patel, M., Berrington, J., Dorling, J., Embleton, N. D., Heath, P. T., Oddie, S., McGuire, W., Ainsworth, S., Boyle, E., Clarke, P., . . . Manjunatha, C. M. (2019). Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)32221-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.